July 4, 2023
ISOFOL PRESENTS CONCLUSIONS FROM
THE IN-DEPTH ANALYSIS OF THE AGENT STUDY
June 22, 2023
ISOFOL´S BOARD OF DIRECTORS APPOINTS
ROGER TELL AS ACTING CEO OF THE COMPANY
This website is intended for use by residents of Sweden only
Isofol Medical AB (publ) is developing the drug candidate arfolitixorin with the aim of increasing the efficacy of current standard treatments for colorectal cancer and certain other tumor diseases. A Phase III study of arfolitixorin has been completed and the company is now evaluating opportunities to advance the drug candidate toward a marketing authorization application by conducting additional studies and entering potential partnerships. Isofol Medical AB (publ) is traded on Nasdaq Stockholm.
- November 10, 2023 - November 10, 2023
Interim report July-September 2023
- February 20, 2024 - February 20, 2024
Media – Lates pressreleases
INVESTORS – Latest reports and presentations
Stay updated on the latest news by
following Isofol on Linkedin.